PMID- 33866774
OWN - NLM
STAT- MEDLINE
DCOM- 20220308
LR  - 20240215
IS  - 2233-6087 (Electronic)
IS  - 2233-6079 (Print)
IS  - 2233-6079 (Linking)
VI  - 46
IP  - 1
DP  - 2022 Jan
TI  - Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a 
      Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors.
PG  - 63-70
LID - 10.4093/dmj.2020.0253 [doi]
AB  - BACKGROUND: It is not known which type 2 diabetes mellitus (T2DM) patients would 
      most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment. We aimed to 
      investigate the predictors of response to DPP-4 inhibitors considering degree of 
      DPP-4 inhibition. METHODS: This study is a post hoc analysis of a 24-week, 
      randomized, double-blind, phase III trial that compared the efficacy and safety 
      of a DPP-4 inhibitor (gemigliptin vs. sitagliptin) in patients with T2DM. 
      Subjects were classified into tertiles of T1 <65.26%, T2=65.26%-76.35%, and T3 
      >/=76.35% by DPP-4 inhibition. We analyzed the change from baseline in glycosylated 
      hemoglobin (HbA1c) according to DPP-4 inhibition with multiple linear regression 
      adjusting for age, ethnicity, body mass index, baseline HbA1c, and DPP-4 activity 
      at baseline. RESULTS: The mean age was greater in the high tertile group compared 
      with the low tertile group (T1: 49.8+/-8.3 vs. T2: 53.1+/-10.5 vs. T3: 55.3+/-9.5, 
      P<0.001) of DPP-4 inhibition. Although HbA1c at baseline was not different among 
      tertiles of DPP-4 inhibition (P=0.398), HbA1c after 24-week treatment was lower 
      in the higher tertile compares to the lower tertile (T1: 7.30%+/-0.88% vs. T2: 
      7.12%+/-0.78% vs. T3: 7.00%+/-0.78%, P=0.021). In multiple regression analysis, DPP-4 
      enzyme inhibition rate was not a significant determent for HbA1c reduction due to 
      age. In subgroup analysis by tertile of DPP-4 inhibition, age was the only 
      significant predictor and only in the highest tertile (R2=0.281, B=-0.014, 
      P=0.024). CONCLUSION: This study showed that HbA1c reduction by DPP-4 inhibitor 
      was associated with increasing age, and this association was linked with higher 
      DPP-4 inhibition.
FAU - Hong, Sangmo
AU  - Hong S
AD  - Department of Internal Medicine, Hanyang University Guri Hospital, Hanyang 
      University College of Medicine, Seoul, Korea.
FAU - Jung, Chang Hee
AU  - Jung CH
AD  - Department of Internal Medicine, Asan Medical Center, University of Ulsan College 
      of Medicine, Seoul, Korea.
FAU - Han, Song
AU  - Han S
AD  - Life Sciences, LG Chem Ltd., Seoul, Korea.
FAU - Park, Cheol-Young
AU  - Park CY
AD  - Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan 
      University School of Medicine, Seoul, Korea.
LA  - eng
PT  - Journal Article
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20210419
PL  - Korea (South)
TA  - Diabetes Metab J
JT  - Diabetes & metabolism journal
JID - 101556588
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
SB  - IM
MH  - Blood Glucose
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - *Dipeptidyl-Peptidase IV Inhibitors/pharmacology/therapeutic use
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
PMC - PMC8831807
OTO - NOTNLM
OT  - Aged
OT  - Diabetes mellitus
OT  - Dipeptidyl-peptidase IV inhibitors
OT  - Glycated hemoglobin A
COIS- CONFLICTS OF INTEREST Sangmo Hong, Chang Hee Jung, and Cheol-Young Park had no 
      potential conflict of interest relevant to this article. Song Han was hired by LG 
      Chem Ltd., Seoul.
EDAT- 2021/04/20 06:00
MHDA- 2022/03/09 06:00
PMCR- 2022/01/01
CRDT- 2021/04/19 03:30
PHST- 2020/10/23 00:00 [received]
PHST- 2021/01/26 00:00 [accepted]
PHST- 2021/04/20 06:00 [pubmed]
PHST- 2022/03/09 06:00 [medline]
PHST- 2021/04/19 03:30 [entrez]
PHST- 2022/01/01 00:00 [pmc-release]
AID - dmj.2020.0253 [pii]
AID - dmj-2020-0253 [pii]
AID - 10.4093/dmj.2020.0253 [doi]
PST - ppublish
SO  - Diabetes Metab J. 2022 Jan;46(1):63-70. doi: 10.4093/dmj.2020.0253. Epub 2021 Apr 
      19.